

Jessica Ochalek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7536959/publications.pdf>

Version: 2024-02-01

17
papers

559
citations

933447

10
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

805
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. <i>BMJ Global Health</i> , 2018, 3, e000964.	4.7	181
2	Cost-Effectiveness Thresholds: the Past, the Present and the Future. <i>Pharmacoeconomics</i> , 2018, 36, 509-522.	3.3	124
3	Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. <i>Pharmacoeconomics</i> , 2020, 38, 1319-1331.	3.3	48
4	Supporting the development of a health benefits package in Malawi. <i>BMJ Global Health</i> , 2018, 3, e000607.	4.7	42
5	What next after GDP-based cost-effectiveness thresholds?. <i>Gates Open Research</i> , 2020, 4, 176.	1.1	36
6	Accounting for Timing when Assessing Health-Related Policies. <i>Journal of Benefit-Cost Analysis</i> , 2019, 10, 73-105.	1.2	17
7	Valuing health outcomes: developing better defaults based on health opportunity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 729-736.	1.4	16
8	Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. <i>Clinical Therapeutics</i> , 2020, 42, 44-59.e2.	2.5	16
9	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43.	3.3	16
10	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. <i>BMJ Global Health</i> , 2020, 5, e003006.	4.7	14
11	Causal effects of HIV on employment status in low-income settings. <i>Economics and Human Biology</i> , 2017, 27, 248-260.	1.7	10
12	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	2.1	10
13	A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 7.	1.5	9
14	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. <i>Health Policy and Planning</i> , 2022, 37, 45-54.	2.7	8
15	Squaring the cube: Towards an operational model of optimal universal health coverage. <i>Journal of Health Economics</i> , 2020, 70, 102282.	2.7	6
16	Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	1.5	5
17	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. <i>BMJ Global Health</i> , 2021, 6, e007047.	4.7	1